Biomimetic Brain-Targeted Drug Delivery System for the Treatment of Brain Diseases.

The blood-brain barrier (BBB) effectively blocks most drugs from entering the central nervous system, posing significant challenges to the treatment of brain diseases, such as cerebrovascular disorders, neurodegenerative conditions, and brain tumors. In recent years, biomimetic braintargeted drug delivery systems (BBDDSs) have garnered substantial attention for their potential to overcome these obstacles. BBDDSs employ natural biological materials in combination with synthetic nanoparticles to create delivery systems that mimic endogenous biological processes, enabling the penetration of the BBB and facilitating brain-targeting efficacy.

Brain-targeted M2 macrophage membrane-hybrid biomimetic liposomes for treatment of traumatic brain injury.

Traumatic brain injury (TBI) is highly incidental but effective solutions are absent. Moreover, the secondary injury following TBI is arising due to the Ca influx of injured neural cells. Here, a Ca influx inhibitor, nimodipine, was loaded in M2 macrophage membrane-hybrid biomimetic liposomes (NM2Ls).